Cited by 2,709

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Immune Checkpoint Blockade in Cancer Therapy

Open access

Postow, Michael A., Callahan, Margaret K., Wolchok, Jedd D.·2015·Journal of Clinical Oncology

DOI 10.1200/jco.2014.59.4358

Open this paper in CoChat — free account

Abstract

Immunologic checkpoint blockade with antibodies that target cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) and the programmed cell death protein 1 pathway (PD-1/PD-L1) have demonstrated promise in a variety of malignancies. Ipilimumab (CTLA-4) and pembrolizumab (PD-1) are approved by the US Food and Drug Administration for the treatment of advanced melanoma, and additional regulatory approvals are expected across the oncologic spectrum for a variety of other agents that target these pathways. Treatment with both CTLA-4 and PD-1/PD-L1 blockade is associated with a unique pattern of adverse events called immune-related adverse events, and occasionally, unusual kinetics of tumor response are seen. Combination approaches involving CTLA-4 and PD-1/PD-L1 blockade are being investigated to determine whether they enhance the efficacy of either approach alone. Principles learned during the development of CTLA-4 and PD-1/PD-L1 approaches will likely be used as new immunologic checkpoint blocking antibodies begin clinical investigation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2014.59.4358

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citation
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citation
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Self-citation
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Self-citation
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4
Qureshi, O. S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C., Schmidt, E. M., Baker, J., Jeffery, L. E., Kaur, S., Briggs, Z., et al. (2011) · Science · doi:10.1126/science.1202947 · Cited by 1,860
CTLA-4 is a second receptor for the B cell activation antigen B7.
Linsley, P. S., Brady, W., Urnes, M., Grosmaire, L. S., Damle, N. K., & Ledbetter, J. A. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.3.561 · Cited by 1,685
Cancer regression and autoimmunity induced by cytotoxic t lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
Kwon, E. D., Drake, C. G., Scher, H. I., Fizazi, K., Bossi, A., van den Eertwegh, A. J. M., Krainer, M., Houede, N., Santos, R., Mahammedi, H., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70189-5 · Cited by 1,511
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415
Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation
van Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020 · cited 1×
“body blockade of CTLA-4 could result in antitumor immunity in preclinical models.(8,9)”
Background
Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206
Ribas, A., Camacho, L. H., Lopez-Berestein, G., Pavlov, D., Bulanhagui, C. A., Millham, R., Comin-Anduix, B., Reuben, J. M., Seja, E., Parker, C. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.109 · Cited by 591
Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma
Weber, J. S., Kudchadkar, R. R., Yu, B., Gallenstein, D., Horak, C. E., Inzunza, H. D., Zhao, X., Martinez, A. J., Wang, W., Gibney, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4802 · Cited by 535
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
Hamid, O., Schmidt, H., Nissan, A., Ridolfi, L., Aamdal, S., Hansson, J., Guida, M., Hyams, D. M., Gómez, H., Bastholt, L., et al. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-204 · Cited by 534
Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements
Nishino, M., Giobbie-Hurder, A., Gargano, M., Suda, M., Ramaiya, N. H., & Hodi, F. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0895 · Cited by 522
Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival
Delyon, J., Mateus, C., Lefeuvre, D., Lanoy, E., Zitvogel, L., Chaput, N., Roy, S., Eggermont, A. M. M., Routier, E., & Robert, C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt027 · Cited by 318
Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma
Simeone, E., Gentilcore, G., Giannarelli, D., Grimaldi, A. M., Caracò, C., Curvietto, M., Esposito, A., Paone, M., Palla, M., Cavalcanti, E., et al. (2014) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-014-1545-8 · Cited by 253
Infliximab in the Treatment of Anti-CTLA4 Antibody (Ipilimumab) Induced Immune-Related Colitis
Minor, D. R., Chin, K., & Kashani-Sabet, M. (2009) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2008.0607 · Cited by 120

Research works printed but not linked: 85

10.1126/science.1131078 · DOI · Paper page
10.1073/pnas.162359999 · DOI · Paper page
10.1084/jem.183.6.2533 · DOI · Paper page
10.1016/1074-7613(95)90125-6 · DOI · Paper page
10.1126/science.271.5256.1734 · DOI · Paper page
10.1073/pnas.0712237105 · DOI · Paper page
10.1200/JCO.2012.44.6112 · DOI
10.1093/annonc/mdt161 · DOI
10.1158/1078-0432.CCR-11-1823 · DOI · Paper page
Schadendorf D, European Cancer Congress 2013 (ECCO-ESMO-ESTRO)
10.1200/JCO.2011.38.4032 · DOI · Paper page
10.1097/CJI.0b013e31829fb7a2 · DOI · Paper page
10.1093/annonc/mdt107 · DOI · Paper page
10.1016/S1470-2045(13)70381-4 · DOI · Paper page
10.1002/j.1460-2075.1992.tb05481.x · DOI · Paper page
10.1084/jem.192.7.1027 · DOI · Paper page
10.1084/jem.20051776 · DOI
10.1126/science.291.5502.319 · DOI · Paper page
10.1016/j.imlet.2010.09.022 · DOI
Infante JR, 2013, J Clin Oncol, 31
10.1056/NEJMoa1305133 · DOI · Paper page
Weber J, 2014 European Society of Medical Oncology Congress
10.1016/S0140-6736(14)60958-2 · DOI · Paper page
10.1158/1078-0432.CCR-07-4079 · DOI · Paper page
10.1200/JCO.2012.48.3685 · DOI · Paper page
10.1016/S1470-2045(13)70551-5 · DOI
10.1016/j.immuni.2007.05.016 · DOI · Paper page
Powles T, 2014, J Clin Oncol, 32
Segal NH, 2014, J Clin Oncol, 32
Herbst RS, 2013, J Clin Oncol, 31
Heery CR, 2014, J Clin Oncol, 32
Saenger YM, 2008, Cancer Immun, 8, 1
10.1158/1078-0432.CCR-09-1624 · DOI · Paper page
10.1093/jnci/djq310 · DOI
Hodi FS, 2014, J Clin Oncol, 32
10.1200/JCO.2001.19.13.3210 · DOI
10.1016/j.jaad.2014.02.035 · DOI
10.1002/cncr.27969 · DOI · Paper page
10.1097/CMR.0b013e32835fb524 · DOI
10.1097/01.cji.0000178913.41256.06 · DOI · Paper page
10.1007/s11102-009-0193-z · DOI · Paper page
10.1097/00002371-200411000-00008 · DOI
10.1093/annonc/mdr028 · DOI
10.1007/s00262-008-0642-y · DOI · Paper page
10.1097/CJI.0b013e31819aa40b · DOI
10.1007/s00262-008-0627-x · DOI
10.1007/s10637-014-0092-7 · DOI
10.1186/2051-1426-2-19 · DOI
10.1007/s00262-014-1607-y · DOI
10.1186/s40425-014-0035-z · DOI
Gettings EJ, Mult Scler
10.1158/1078-0432.CCR-12-3080 · DOI
10.1158/1078-0432.CCR-12-2625 · DOI
10.1186/1479-5876-10-146 · DOI
10.2967/jnumed.109.070946 · DOI
10.1073/pnas.1110814108 · DOI · Paper page
Postow MA, 2013, J Clin Oncol, 31
10.1158/1078-0432.CCR-10-0569 · DOI · Paper page
10.1158/2326-6066.CIR-13-0020 · DOI · Paper page
10.1007/s00262-011-1172-6 · DOI
10.1200/JCO.2012.47.7521 · DOI · Paper page
Grosso J, 2013, J Clin Oncol, 31
10.1158/1078-0432.CCR-13-3271 · DOI · Paper page
10.1158/1078-0432.CCR-13-2797 · DOI · Paper page
10.1038/nm1517 · DOI · Paper page
10.1038/nrclinonc.2010.223 · DOI
Weber J, 2013, Cancer Immun, 13, 7
10.1200/JCO.2013.52.1377 · DOI
10.1056/NEJMc1302338 · DOI · Paper page
Puzanov I, 2014, J Clin Oncol, 32
10.1002/cncr.25639 · DOI
Amin A, 2014, J Clin Oncol, 32
10.1093/jnci/djs629 · DOI
Demaria S, 2005, Clin Cancer Res, 11, 728, 10.1158/1078-0432.728.11.2 · DOI
10.1172/JCI67313 · DOI · Paper page
10.1056/NEJMoa1112824 · DOI · Paper page
10.1056/NEJMcpc1302332 · DOI
10.1158/2326-6066.CIR-13-0115 · DOI · Paper page
10.4161/onci.28780 · DOI · Paper page
10.1158/2326-6066.CIR-13-0082 · DOI
Gibney G, 2014, J Clin Oncol, 32
Puzanov I, 2014, J Clin Oncol, 32
Hodi FS, 2013, J Clin Oncol, 31
Sznol M, 2014, J Clin Oncol, 32
10.1093/annonc/mdu344.1 · DOI

Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Self-citation
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
PD-L1 expression as a predictive biomarker in cancer immunotherapy
Patel, S. P., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0983 · Cited by 2,291
Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy
Ribas, A., Dummer, R., Puzanov, I., VanderWalde, A., Andtbacka, R. H. I., Michielin, O., Olszanski, A. J., Malvehy, J., Cebon, J., Fernandez, E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.027 · Cited by 1,520

See all 2,709

Authors: Postow, M. A., Callahan, M. K., & Wolchok, J. D.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2015-06-10
Volume: 33
Issue: 17
Pages: 1974-1982
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2014.59.4358
OpenAlex: W2096322385
Cited by: 2,709
References: 24
FWCI: 117.79
Type: journal article
Language: en
Open access: green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

Immune Checkpoint Blockade in Cancer Therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Metadata

Record

About these checks

Data sources